Programs
Campuses
Research & Impact
About Us

Sudarshan Kriya

Sudarshan Kriya

sky

sky

Evidence-Based Breathing Practice

Evidence-Based Breathing Practice

Peer-reviewed research demonstrating measurable improvements in stress, depression, anxiety, and biological health markers across diverse populations.

250 +

250 +

Published Studies
Published Studies

15,000 +

15,000 +

Research Participants
Research Participants

40 +

40 +

Countries Studied
Countries Studied

Rigorous Scientific Methodology

All studies featured utilize randomized controlled trials (RCTs) or controlled clinical designs with validated assessment tools and peer review.
All studies featured utilize randomized controlled trials (RCTs) or controlled clinical designs with validated assessment tools and peer review.

RCT Design

Randomized controlled trials with proper control groups and blinding protocols

Validated Scales

HAM-A, HAM-D, PSS-10, and other clinically validated assessment instruments

Biomarkers

Objective biological measurements including blood work and physiological indicators

Diverse Cohorts

Studies across student, clinical, and general populations with varied demographics

RCT

8 Weeks

N = 30

University Population

Reduces Stress and Depression
in College Students

Reduces Stress and Depression
in College Students

Randomized controlled trial comparing SKY breathing techniques with Emotional Intelligence training and Mindfulness-Based Stress Reduction among university students over 8 weeks (30 contact hours).

Primary Outcome

−0.32 β

Stress Reduction (PSS-10)

Standardized beta coefficient indicating significant decrease in perceived stress levels

0.29

Depression

+ 0.30

Positive Affect

+ 0.26

Mindfulness

+ 0.21

Social Connection

Effect Sizes Comparison

Stress Reduction

β = −0.32

Depression

β = −0.29

Positive Affect

β = +0.30

Mindfulness

β = +0.26

Social Connection

β = +0.21

Social Connection

Control (n=47)

SKY (n=29)

EI (n=21)

MBSR (n=34)

What This Means

After 8 weeks of SKY practice, college students showed measurable reductions in stress and depression symptoms, alongside improvements in emotional well-being, mindfulness awareness, and social connectedness. These effects were statistically significant compared to control groups, demonstrating SKY’s efficacy in supporting mental health during academically demanding periods.

Clinical Trial

4 Weeks

N = 45

Hospitalized Patients

Clinically Significant Remission in Severe Depression

Controlled clinical study comparing SKY with electroconvulsive therapy (ECT) and imipramine medication in hospitalized patients diagnosed with melancholic depression over 4 weeks of treatment.

SKY Primary Outcome

67 %

Remission Rate

10 of 15 patients achieved full remission criteria within 4 weeks

Treatment Comparison

Sudarshan Kriya Yoga (SKY)

n = 15

67%

10/15

Imipramine (Medication)

n = 15

73%

11/15

Electroconvulsive Therapy (ECT)

n = 15

93%

14/15

45

Total Enrolled

3

Equal Groups

4

Weeks Duration

What This Means

In severe, hospitalized melancholic depression, SKY breathing practice demonstrated substantial remission rates within just 4 weeks—comparable to pharmaceutical intervention and approaching ECT outcomes. This suggests SKY can be a valuable treatment option even for clinically severe depression, offering a non-pharmacological pathway to recovery with significant clinical efficacy.

Longitudinal Study

3 Month Follow-up

N = 30

Drug-Free Protocol

Improvement Without Medication

Study examining SKY as a standalone intervention for depression without pharmaceutical support, with assessments at baseline, 1 month, and 3 months to evaluate sustained benefits.

Response Rate

73%

Response Rate

22

Responded

8

Non-Responders

Participant Outcomes

Total Participants

30

Positive Response

22

Response Rate

73%

Medication Used

0

What This Means

Nearly 3 in 4 participants improved by practicing SKY alone, without medication. This demonstrates that breathing-based interventions can serve as effective standalone treatments for depression, offering a non-pharmaceutical pathway that may be particularly valuable for individuals seeking drug-free approaches or those who cannot tolerate psychiatric medications.

Clinical Pilot Study

Adjunctive Treatment

4-Week Follow-up

N = 41 Enrolled

Relief for Treatment-Resistant Anxiety

An open-label pilot study examined SKY as an addition to existing treatment for adults with generalized anxiety disorder who had not achieved remission after at least eight weeks of conventional care. Outcomes were measured using the Hamilton Anxiety Rating Scale, or HAM-A.

PRIMARY RESPONSE

73%

73%

Response Rate

At least a 50% reduction in HAM-A scores

21 of 29 participants included in the outcome analysis

REMISSION

REMISSION


41%

41%

Achieved Remission

HAM-A score of 7 or lower

12 of 29 participants included in the outcome analysis

STATISTICAL RESULT

4.59

4.59

t-value

P < 0.01

P < 0.01


Significant pre-to-post reduction in anxiety scores

PARTICIPANT FLOW

41

Enrolled

Treatment-resistant GAD

31

Completed

76% completion rate

29

Outcome Analysis

Included in analysis

21

Responded

≥50% HAM-A reduction

12

Reached Remission

HAM-A ≤7

73%

Response Rate

41%

Remission Rate

4.59

t-value

P < 0.01

Significance

What This Means

In this small open-label pilot, SKY was used alongside standard treatment rather than replacing it. Participants showed significant improvement in anxiety, including a 73% response rate and a 41% remission rate. The findings are promising for people who had not previously reached remission, while larger controlled studies are still needed.

Clinical Pilot Study

Adjunctive Treatment

4-Week Follow-up

N = 41 Enrolled

Relief for Treatment-Resistant Anxiety

An open-label pilot study examined SKY as an addition to existing treatment for adults with generalized anxiety disorder who had not achieved remission after at least eight weeks of conventional care. Outcomes were measured using the Hamilton Anxiety Rating Scale, or HAM-A.

PRIMARY RESPONSE

73%

Response Rate

At least a 50% reduction in HAM-A scores

21 of 29 participants included in the outcome analysis

REMISSION

41%

Achieved Remission

HAM-A score of 7 or lower

12 of 29 participants included in the outcome analysis

STATISTICAL RESULT

4.59

t-value

P < 0.01

Significant pre-to-post reduction in anxiety scores

PARTICIPANT FLOW

41

Enrolled

Treatment-resistant GAD

31

Completed

76% completion rate

29

Outcome Analysis

Included in analysis

21

Responded

≥50% HAM-A reduction

12

Reached Remission

HAM-A ≤7

73%

Response Rate

41%

Remission Rate

4.59

t-value

P < 0.01

Significance

What This Means

In this small open-label pilot, SKY was used alongside standard treatment rather than replacing it. Participants showed significant improvement in anxiety, including a 73% response rate and a 41% remission rate. The findings are promising for people who had not previously reached remission, while larger controlled studies are still needed.

RCT

6 Week Study

N = 40 Analyzed

Biomarker Assessment

Measurable Biological Changes

A randomized controlled trial measured lipid and blood-cell markers in university students at baseline, during an examination period, and after three and six weeks of SKY and pranayama practice.

Primary Outcome

Triglycerides

Decreased

Statistical Significance

P < 0.001

Time Point

6 Weeks

Total Cholesterol
P < 0.05
VLDL Cholesterol
P < 0.01
Lymphocytes
P < 0.01

STUDY TIMELINE & MEASUREMENTS

Baseline

Initial blood work and stress assessment

Triglycerides · Cholesterol · VLDL · Lymphocytes

Exam Period

During high-stress examination period

↑ Cholesterol increased (P < 0.01)

↑ Triglycerides increased (P < 0.001)

3 Weeks Post-Intervention

Mid-point assessment
Markers trending toward improvement

6 Weeks Post-Intervention

Final assessment showing significant changes

All primary markers improved
Effects sustained over time

BIOMARKER CHANGES OVER TIME

Biomarker

Baseline

Exam Period

3 Weeks

6 Weeks

Significance

Triglycerides

Normal

↑ Elevated

↓ Decreasing

↓ Reduced

P < 0.001

Total Cholesterol

Normal

↑ Elevated

↓ Decreasing

↓ Reduced

P < 0.05

VLDL

Normal

Stable

↓ Decreasing

↓ Reduced

P < 0.01

Lymphocytes

Normal

Stable

↑ Increasing

↑ Elevated

P < 0.01

43

Enrolled

40

Analyzed

19

Control Group

21

SKY Group

What This Means

SKY influenced measurable biological stress markers—not just mood or self-reported symptoms. The practice led to significant improvements in cardiovascular risk factors (triglycerides, cholesterol) and immune function (lymphocytes), demonstrating that breathing techniques can produce objective, physiologically measurable changes in the body’s stress response systems. This provides concrete biological evidence for SKY’s health benefits beyond subjective well-being.